Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Grifols, S.A.

Grifols Biopharma

Grifols Diagnostic

Grifols Healthcare Solutions

Grifols Bio Supplies

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. 

A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. 

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. 

Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

With a workforce of over 24,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.

People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.

In 2022, Forbes has recognized Grifols as one of the “Best Employers for Women,” one of “America’s Best Large Employers” and one of the “75 Best Companies to Work for” in Spain.

To maintain a positive community and overall respectful communication, please keep our community guidelines in mind. You will find a full version of our guidelines at https://www.grifols.com/en/grifols-social-media-community-guidelines

Alkahest

Celyad

GigaGen

VCN Biosciences

Grifols

We've always embraced challenges with determination and innovation, and the Year of the Dragon  presents us with new opportunities to excel. 

🐉 Let us harness the energy of this majestic creature to propel innovation, foster collaboration, embrace transformation and achieve unprecedented heights. 

✨ May this year bring prosperity, joy, and fulfillment to you and your loved ones. 

Share Grifols greeting 👇 with your team and spread the luck!

In the dynamic world of biotech, safeguarding data is paramount. At Grifols, we're unwavering in our commitment to cybersecurity, ensuring trust with our stakeholders.  

Our investment in cutting-edge cybersecurity tech shields our research, proprietary data, and collaborations, aimed to set into place a secure digital ecosystem. In this journey, the Information Security Office is pivotal in building trust, as well as securing clients, patients, donors, investors, and employees' data within our systems, in compliance with stringent regulations.  

On #WomeninSTEM Day, we would like you to meet Susana Calvo, who is leading cybersecurity at the company. 

#IT #engineering #GrifolsTeam

Did you know that it was Víctor Grífols i Lucas who developed a centrifuge to perform plasmapheresis next to the donor?  

This was in 1965, when Grifols succeeded, for the first time, in making it possible to perform the blood donation, separation and reinfusion of blood cells immediately after their extraction.  

Until then, technical limitations meant that the separation of blood components took place in a centrifuge containing multiple donations. With this development, every donor had their own centrifuge within the donation cabin, allowing plasmapheresis to be performed in situ.  

Continuous centrifuges in use today are based on these principles and are a testament to the power of innovation to overcome health risks. 

#healthcareinnovation #Since1909

We are excited to announce the winners of the first Grifols Women in Leadership Awards.  

Johana Rummings, Director of Operations in plasma management, has been honored in the category of Inspirational Leader for her rigorous work, contributions to the business and ability to inspire the next generation of leaders.   

Ester Sánchez, Project Manager in Canada, has been recognized as an Emerging Leader, due to her contribution to high-priority projects in #engineering, her professionalism and exceptional results which demonstrate her great potential as a leader within the business.  

The Grifols’ Women in Leadership Awards were created to honor Dr. Marilyn Rosa-Bray’s legacy and to continue her work on gender equity and the development of people.  

👏 More than 250 outstanding women were nominated by their peers for the work they do and the contributions they make to the company. Increasing the presence of women in senior management is a key priority and one of our 2030 Agenda goals.  

#womenleadership #genderequity #PositiveImpact

⚽ The ties have been set for the road to the Bilbao final.

Ajax, Barcelona, Benfica, Brann, Chelsea, Häcken, Lyon and Paris Saint-Germain will compete for quarter-finals in UEFA Women's Champions League.  Kadidiatou Diani, Ada Hegerberg, Sam Kerr and Salma Paralluelo are so far the top scorers of the tournament.   

The level of women's football is flying high. As a proud sponsor of UEFA Women’s Football competitions, we deeply believe that in sports, we all play a role.   

We know that all the players will give their best. Which teams do you think will made it to the semi-finals?  

#UEFA #UWCL #womenssports #GrifolsSocialImpact

Today Grifols announced it has appointed Nacho Abia as new CEO. He will join the company April 1 and report to Thomas Glanzmann, our Executive Chairman. 

Raimon Grifols and Victor Grifols Deu are stepping down from their executive positions as CCO and COO, respectively, and will remain as members of the Grifols Board of Directors as part of a long-planned strategy led by Raimon, Victor and the Board to separate ownership from management. 

For more information, please see the press release.

#WeAreHealthcare

We are proud to announce that Prolastin®, Grifols’ trusted alpha1-proteinase inhibitor [human] that for more than 35 years has treated patients living with alpha1-antitrypsin deficiency (alpha-1), is now available in 4- and 5-gram vial sizes in Germany and Denmark. 

Available in additional European markets throughout 2024, the new vial sizes will enable healthcare professionals to meet more efficiently the dosing needs of alpha-1 patients.   

#geneticcopd #respiratorycare #WhatWeDoMatters

It's all about the patients. Our motivation is not the manufacture of products, but a mission to transform lives. 

🔬 Much of our focus is on rare diseases such as primary immunodeficiency,  alpha₁-antitrypsin deficiency, bleeding disorders, and chronic inflammatory demyelinating polyneuropathy. 

Our mission is to turn donors' generosity into better lives for patients around the world. 

#WhatWeDoMatters #raredisease

We are pleased to welcome two new executives to Grifols. 

Roland Wandeler, Ph.D., has joined as President of our Grifols Biopharma Business Unit, and Camille Alpi as Chief Human Resources and Talent Officer. Both have longstanding global experience in their respective fields and will make great contributions to the future of Grifols. 

We are delighted to have them. 
For more information, please see the press release. 

#biopharma #WeAreHealthcare

Innovation is in our DNA. 

Our robust therapeutic portfolio is the result of keen insights into multiple disease states for which we’re developing potential treatments, including plasma and non-plasma solutions alike. 

The next wave of Grifols innovation has the potential to significantly transform #healthcare. Discover our key therapeutic areas. 👇 

#WeAreHealthcare  #healthcareinnovation

PNK:GIFLF

Grifols, S.A.

Last Close

10.59

24/09 20:00

Market Cap

5.87B

Beta: 0.43

Volume Today

142

Avg: 648

People Not Available